Endomagnetics→Hologic
Acquisition · Cash · HOLX · announced May 20, 2024
Announced
May 20, 2024
Closed
Jul 25, 2024
Economics
Cash()
Pre-deal · pre-deal mark: 2024, year precision · rounding grid ±$100M · Fierce Healthcare — acquisition coverage, 2024
~$310M (Nasdaq/Hologic press release)
Target
Endomagnetics
Breast Health · Clinical / therapeutic
HQ Cambridge, UK · Founded 2007
Magnetic marker and localization technology for breast cancer surgery (Magseed, Sentimag)
- Nasdaq press release - Hologic acquisition (Jul 25, 2024)
- Endomagnetics company website - endomagnetics.com
Acquirer
Hologic (HOLX)
Breast Health
HQ Marlborough, MA
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Added magnetic seed and sentinel lymph node biopsy technology to breast health portfolio — expands international presence (UK-based)
Evidence ladder
Secondary (press / IR)
Nasdaq press release (Jul 25, 2024)
Limitations
- Single-source or weak corroboration — treat valuation and timing as directional.
- ~$310M (Nasdaq/Hologic press release)
- Pre-deal valuation sourced from: Fierce Healthcare — acquisition coverage, 2024. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Breast Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Biotheranostics | Hologic | Jan 5, 2021 | same acquirer |
Other verified deals by Hologic
Acquirer program history not already listed as a valuation peer or adjacency row.
| Target | Acquirer | Announced | Value | Sector |
|---|---|---|---|---|
| Gynesonics | Hologic | Sep 15, 2024 | Gynecological Surgery | |
| Bolder Surgical | Hologic | Oct 14, 2021 | Gynecological Surgery | |
| Acessa Health | Hologic | Aug 25, 2020 | Gynecological Surgery | |
| SuperSonic Imagine | Hologic | Jun 21, 2019 | Breast Health | |
| Focal Therapeutics | Hologic | Sep 26, 2018 | Breast Health |
Patient empowerment context
Empowerment context — Endomagnetics
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should)37%cited HLTH 2022
Other curated mappings on these gaps: Biotheranostics, Genomic Health, Foundation Medicine, Counsyl
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 1 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.